Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Psychol Med ; 45(15): 3341-54, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26169626

ABSTRACT

BACKGROUND: Although cognitive deficits in patients with schizophrenia are rooted early in development, the impact of psychosis on the course of cognitive functioning remains unclear. In this study a nested case-control design was used to examine the relationship between emerging psychosis and the course of cognition in individuals ascertained as clinical high-risk (CHR) who developed psychosis during the study (CHR + T). METHOD: Fifteen CHR + T subjects were administered a neurocognitive battery at baseline and post-psychosis onset (8.04 months, s.d. = 10.26). CHR + T subjects were matched on a case-by-case basis on age, gender, and time to retest with a group of healthy comparison subjects (CNTL, n = 15) and two groups of CHR subjects that did not transition: (1) subjects matched on medication treatment (i.e. antipsychotics and antidepressants) at both baseline and retesting (Meds-matched CHR + NT, n = 15); (2) subjects unmedicated at both assessments (Meds-free CHR + NT, n = 15). RESULTS: At baseline, CHR + T subjects showed large global neurocognitive and intellectual impairments, along with specific impairments in processing speed, verbal memory, sustained attention, and executive function. These impairments persisted after psychosis onset and did not further deteriorate. In contrast, CHR + NT subjects demonstrated stable mild to no impairments in neurocognitive and intellectual performance, independent of medication treatment. CONCLUSIONS: Cognition appears to be impaired prior to the emergence of psychotic symptoms, with no further deterioration associated with the onset of psychosis. Cognitive deficits represent trait risk markers, as opposed to state markers of disease status and may therefore serve as possible predictors of schizophrenia prior to the onset of the full illness.


Subject(s)
Cognition Disorders/etiology , Disease Progression , Psychotic Disorders/complications , Adolescent , Adult , Case-Control Studies , Female , Humans , Male , Prodromal Symptoms , Prospective Studies , Risk , Young Adult
2.
Acta Psychiatr Scand ; 132(1): 60-8, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25572323

ABSTRACT

OBJECTIVE: Cannabis use has been examined as a predictor of psychosis in clinical high-risk (CHR) samples, but little is known about the impact of other substances on this relationship. METHOD: Substance use was assessed in a large sample of CHR participants (N = 370, mean age = 18.3) enrolled in the multisite North American Prodrome Longitudinal Study Phase 1 project. Three hundred and forty-one participants with cannabis use data were divided into groups: No Use (NU, N = 211); Cannabis Use without impairment (CU, N = 63); Cannabis Abuse/Dependence (CA/CD, N = 67). Participants (N = 283) were followed for ≥2 years to determine psychosis conversion. RESULTS: Alcohol (45.3%) and cannabis (38.1%) were the most common substances. Cannabis use groups did not differ on baseline attenuated positive symptoms. Seventy-nine of 283 participants with cannabis and follow-up data converted to psychosis. Survival analysis revealed significant differences between conversion rates in the CA/CD group compared with the No Use (P = 0.031) and CU group (P = 0.027). CA/CD also significantly predicted psychosis in a regression analysis, but adjusting for alcohol use weakened this relationship. CONCLUSION: The cannabis misuse and psychosis association was confounded by alcohol use. Non-impairing cannabis use was not related to psychosis. Results highlight the need to control for other substance use, so as to not overstate the cannabis/psychosis connection.


Subject(s)
Alcohol-Related Disorders/epidemiology , Marijuana Abuse/epidemiology , Psychoses, Substance-Induced/epidemiology , Psychotic Disorders/epidemiology , Risk-Taking , Adolescent , Alcohol-Related Disorders/psychology , Causality , Comorbidity , Disease Progression , Female , Humans , Male , Marijuana Abuse/psychology , Psychoses, Substance-Induced/psychology , Psychotic Disorders/psychology , Risk Assessment , Risk Factors , United States/epidemiology , Young Adult
3.
Psychol Med ; 42(12): 2485-97, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22716931

ABSTRACT

BACKGROUND: Clinical and epidemiological studies suggest an association between cannabis use and psychosis but this relationship remains controversial. METHOD: Clinical high-risk (CHR) subjects (age 12-22 years) with attenuated positive symptoms of psychosis (CHR+, n=101) were compared to healthy controls (HC, n=59) on rates of substance use, including cannabis. CHR+ subjects with and without lifetime cannabis use (and abuse) were compared on prodromal symptoms and social/role functioning at baseline. Participants were followed an average of 2.97 years to determine psychosis conversion status and functional outcome. RESULTS: At baseline, CHR+ subjects had significantly higher rates of lifetime cannabis use than HC. CHR+ lifetime cannabis users (n=35) were older (p=0.015, trend), more likely to be Caucasian (p=0.002), less socially anhedonic (p<0.001) and had higher Global Functioning: Social (GF:Social) scores (p<0.001) than non-users (n=61). CHR+ cannabis users continued to have higher social functioning than non-users at follow-up (p<0.001) but showed no differences in role functioning. A small sample of CHR+ cannabis abusers (n=10) showed similar results in that abusers were older (p=0.008), less socially anhedonic (p=0.017, trend) and had higher baseline GF:Social scores (p=0.006) than non-abusers. Logistic regression analyses revealed that conversion to psychosis in CHR+ subjects (n=15) was not related to lifetime cannabis use or abuse. CONCLUSIONS: The current data do not indicate that low to moderate lifetime cannabis use is a major contributor to psychosis or poor social and role functioning in clinical high-risk youth with attenuated positive symptoms of psychosis.


Subject(s)
Marijuana Abuse/epidemiology , Prodromal Symptoms , Psychoses, Substance-Induced/epidemiology , Psychotic Disorders/diagnosis , Psychotic Disorders/epidemiology , Adolescent , Age of Onset , Causality , Child , Comorbidity , Female , Humans , Illicit Drugs , Male , Marijuana Abuse/complications , Marijuana Abuse/diagnosis , Marijuana Abuse/psychology , New York , Odds Ratio , Psychoses, Substance-Induced/diagnosis , Psychoses, Substance-Induced/psychology , Psychotic Disorders/psychology , Risk Factors , Substance-Related Disorders/complications , Substance-Related Disorders/diagnosis , Substance-Related Disorders/epidemiology , Substance-Related Disorders/psychology , Young Adult
4.
Oper Dent ; 25(4): 311-5, 2000.
Article in English | MEDLINE | ID: mdl-11203836

ABSTRACT

The operating protocols used for finishing composite resins are numerous and affect the success of filling from a mechanical, biological, and aesthetic point of view. The study determined the most favorable finishing for each of the composites considered. The three-dimensional optical profilometry examination was used to obtain qualitative and quantitative measurements of three hybrid composites. Tungsten carbide burs left irregularities harder to eliminate than those caused by diamond burs. Sof-Lex disks and the Enhance System gave good results for the three materials. Charisma presented a good surface regardless of polishing method used. Finishing Z100 and Prisma TPH required a special operating protocol as specified by the manufacturers. This study demonstrated that the finishing procedure for composite materials must be strictly followed to obtain optimal results. Profilometry proved to be an excellent method to study the surface roughness of samples.


Subject(s)
Composite Resins/chemistry , Dental Polishing , Silicon Dioxide , Zirconium , Analysis of Variance , Dental Polishing/methods , Dental Restoration, Permanent/instrumentation , Diamond/chemistry , Equipment Design , Humans , Materials Testing , Optics and Photonics , Surface Properties , Tungsten Compounds/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL